{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:47:32Z","timestamp":1793339252710,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health at Charit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022854","name":"European Cystic Fibrosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","award":["MR\/X00094X\/1"],"award-info":[{"award-number":["MR\/X00094X\/1"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X00094X\/1"],"award-info":[{"award-number":["MR\/X00094X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2025.03.003","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:25:18Z","timestamp":1742358318000},"page":"521-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenic adverse events to CFTR modulators \u2013 An international survey"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7360-6001","authenticated-orcid":false,"given":"Ruth M.","family":"Urbantat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Behan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8997","authenticated-orcid":false,"given":"Sebastian","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-8315","authenticated-orcid":false,"given":"Mirjam","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Naisbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-8852","authenticated-orcid":false,"given":"Jobst F.","family":"Roehmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.03.003_bib0001","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(23)00299-0","article-title":"EPS1.08 Immunogenic adverse events to CFTR modulators \u2013 an international survey","volume":"22","author":"Urbantat","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.03.003_bib0002","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/ppul.25938","article-title":"At-home compounding preparation of slow desensitization of elexacaftor\/tezacaftor\/ivacaftor for delayed hypersensitivity rash","volume":"57","author":"Muirhead","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2025.03.003_bib0003","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.003_bib0004","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaci.2020.05.041","article-title":"Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4(+) T lymphocytes","volume":"147","author":"Roehmel","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jcf.2025.03.003_bib0005","doi-asserted-by":"crossref","first-page":"e13815","DOI":"10.1111\/pai.13815","article-title":"T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis","volume":"33","author":"Semic-Jusufagic","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-247042","article-title":"Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation","volume":"15","author":"Cheng","year":"2022","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.003_bib0007","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/ACI.0b013e328355b849","article-title":"Nonimmediate beta-lactam reactions in patients with cystic fibrosis","volume":"12","author":"Whitaker","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.003_bib0008","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2013.10.002","article-title":"Hypersensitivity to antibiotics in patients with cystic fibrosis","volume":"13","author":"Roehmel","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"19","key":"10.1016\/j.jcf.2025.03.003_bib0009","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2025.03.003_bib0010","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcf.2025.03.003_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2025.03.003_bib0012","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jcf.2022.06.011","article-title":"A case of Elexacaftor-Tezacaftor-ivacaftor induced rash resolving without interruption of treatment","volume":"21","author":"Bhaskaran","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1016\/j.jcf.2025.03.003_bib0013","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jcf.2022.09.002","article-title":"Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"21","author":"Hudson","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2025.03.003_bib0014","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.03.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106878","article-title":"Who are the 10%? - non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies","volume":"199","author":"Desai","year":"2022","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.jcf.2025.03.003_bib0016","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"10408","key":"10.1016\/j.jcf.2025.03.003_bib0017","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.03.003_bib0018","article-title":"Successful desensitization protocol to ivacaftor and a compound of Elexacaftor\/Tezacaftor\/ivacaftor in a delayed hypersensitivity reaction confirmed by lymphocyte transformation test","author":"Mir-Ihara","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.003_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.jcf.2025.03.003_bib0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.5005\/jp-journals-10071-23826","article-title":"Drug-related Stevens-Johnson syndrome and toxic epidermal necrolysis: a review","volume":"25","author":"Arora","year":"2021","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.jcf.2025.03.003_bib0021","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.003_bib0022","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.03.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2025.03.003_bib0024","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/10937404.2023.2261848","article-title":"Drug induced liver injury - a 2023 update","volume":"26","author":"Allison","year":"2023","journal-title":"J Toxicol Environ Health B Crit Rev"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T08:35:22Z","timestamp":1750149322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199325000712"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenic adverse events to CFTR modulators \u2013 An international survey","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}